CBE Spring 2017 Seminar Series Presents a Seminar with Dr. Annelise Barron
- Thursday, April 27, 2017 from 4:10pm to 5:00pm
- Roberts Hall - view map
Dr. Annelise Barron is a W.M. Keck Associate Professor of Bioengineering at Stanford University. At this week's seminar she will present “Antibiofilm activities of peptoid mimics of antimicrobial peptides (ampetoids).” Dr. Barron's research interests are broad and include mimicking host defense/antimicrobial peptides, tissue engineering, DNA analysis technology, capillary electrophoresis, lung surfactants, and genetically engineered proteins. To read more about Dr. Barron's research, go to: https://med.stanford.edu/profiles/annelise-barron
MSU Host: Jeff Heys, Chemical & Biological Engineering
If you would like to meet with Dr. Barron, please contact Dr. Heys at firstname.lastname@example.org
Presentation abstract: Increasingly prevalent resistance of pathogenic bacteria to conventional small-molecule antibiotic drugs is creating an urgent need for the discovery of new classes of antibiotics that are active against biofilms. Bacteria that are multidrug resistant (MDR) are of increasing concern for infectious disease. Current treatment of these infections that involve resistant organisms may require 6-12 months of antibiotic treatment, creating difficulties with compliance. We are continuing to develop oligo-N-substituted glycine (peptoid) mimics of cationic, helical antimicrobial peptides (AMPs), and some of our recently acquired data indicate that peptoids could address the problem of growing resistance. Peptoids have been shown to have extremely broad-spectrum activity, and certain peptoids function well in the presence of serum proteins. Their biophysical mechanism of action makes it difficult for bacteria to evolve resistance to them. We have tested our most promising peptoids, peptides and commercial antibiotics in vitro against bacterial biofilms of a variety of important bacterial organisms. We show that certain peptoids can be as active as the preferred conventional antibiotics against bacterial infections, even at low micromolar doses. Small, structured biomimetic oligomers such as our antimicrobial peptoids may offer a new class of drugs that are useful in treating persistent bacterial infections. Finally, our studies of the mechanism of action of peptoid-based AMP mimics seems to have given us some significant insights into how the natural molecules may act in killing pathogens.
- Center for Biofilm Engineering